Table II.
Clinical information of the patients with rectal cancer.
| A, Sequenced samples | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Metastasis | Sex | Age, years | Tumor location | Tumor size, cm | Pathological type | Vascular invasion | pTNM stagea | Preoperative serum CEA levels (μg/l) | Ki67, %c | Postoperative HHM time, months |
| N1 | NM | F | 58 | Upper | 5.1 | Ulcer type, moderately differentiated adenocarcinoma | − | T4aN0M0, IIb | 5.2 | 45–60 | − |
| N2 | NM | M | 66 | Upper | 4.5 | Ulcer type, moderately or poorly differentiated adenocarcinoma | + | T4aN2bM0, IIIC | 2.8 | <25 | − |
| H1 | HHM | M | 60 | Upper | 6.0 | Ulcer type, moderately or poorly differentiated adenocarcinoma | + | T4bN1M0, IIIC | 2.9 | 50–75 | 48 |
| H2 | HHM | M | 38 | Upper | 5.0 | Ulcer type, moderately or poorly differentiated adenocarcinoma, mucinous partially | + | T4aN1M0, IIIB | 17.0 | 50 | 7 |
| H3b | HHM | F | 77 | Middle | 5.0 | Ulcer type, moderately differentiated adenocarcinoma | − | T3N0M0, IIa | 5.9 | 60 | 15 |
| B, Non-sequenced samples | |||||||||||
| N3 | NM | M | 62 | Middle | 4.3 | Ulcer type, moderately differentiated adenocarcinoma | − | T3N0M0, IIa | 4.7 | 35 | − |
| N4 | NM | M | 73 | Middle | 5.0 | Ulcer type, moderately differentiated adenocarcinoma | + | T3N1M0, IIIB | 16.6 | <25 | − |
| H4 | HHM | M | 61 | Middle | 5.0 | Ulcer type, moderately differentiated adenocarcinoma | + | T4bN2aM0, IIIC | 8.4 | 10 | 10 |
| H5 | HHM | F | 46 | Middle | 5.0 | Ulcer type, moderately differentiated adenocarcinoma | − | T3N0M0, IIa | 3.7 | 65 | 63 |
The TNM stage and histological grading were determined according to the Union for International Cancer Control criteria. The histological classification was based on the WHO criteria. The tumor locations were categorized according to the standard guidelines for clinical practice. Lower rectal cancer, distance between the bottom edge of tumor to anal verge within 3–6 cm; middle rectal cancer, 6–10 cm; upper rectal cancer, 10–15 cm.
The small RNAs length distribution of the H3 sample did not peak at 22 nucleotides, and therefore H3 was not used for additional analysis.
The proportion of Ki67 positive cells. F, female; M, male; NM, non-metastasis; HHM, heterochrony hepatic metastasis; CEA, carcinoembryonic antigen; pTNM, pathological Tumor Node Metastasis; Ki67, antigen Ki67.